NEWARK, Calif., Nov. 17, 2015 /PRNewswire/ — Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. and Canadian rights to cebranopadol and […]
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00PR Newswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngPR Newswire2015-11-17 16:25:002015-11-18 13:05:24Depomed Acquires U.S. Rights to Late-Stage, First-in-Class Pain Product from Grunenthal
